Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ENX-101, a GABA<sub>A</sub> receptor α2,3,5-selective positive allosteric modulator, displays antiseizure effects in rodent seizure and epilepsy models.

Epilepsia·2025

Same author

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy.

Epilepsia open·2025

Same author

Allopregnanolone as an Adjunct Therapy to Midazolam is More Effective Than Midazolam Alone in Suppressing Soman-Induced Status Epilepticus in Male Rats.

CNS neuroscience & therapeutics·2025

Same author

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.

JAMA neurology·2023

Same author

Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs.

Epilepsia open·2023

Same author

A randomized, open-label, two-treatment crossover study to evaluate the effect of food on the pharmacokinetics of diazepam nasal spray in healthy adults.

Epilepsia·2022

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Neurosteroid replacement therapy for catamenial epilepsy.

Doodipala S Reddy¹, Michael A Rogawski

¹Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M System Health Science Center, College Station, Texas 77843, USA. reddy@medicine.tamhsc.edu

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics

|April 1, 2009

Summary

Catamenial epilepsy involves cyclical seizures linked to menstruation, potentially caused by falling progesterone and neurosteroid withdrawal. Neurosteroid replacement therapy, using drugs like ganaxolone, may prevent these perimenstrual seizure exacerbations.

More Related Videos

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

Related Experiment Videos

Last Updated: Jun 24, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Manipulation of Epileptiform Electrocorticograms (ECoGs) and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

Area of Science:

Neuroscience
Pharmacology
Epilepsy Research

Background:

Perimenstrual catamenial epilepsy affects many women with drug-refractory epilepsy, characterized by cyclical seizure exacerbations.
This heightened seizure susceptibility is linked to the decline in progesterone and its metabolite, allopregnanolone, a GABA(A) receptor modulator, during menstruation.

Purpose of the Study:

To investigate the neurobiological mechanisms underlying perimenstrual catamenial epilepsy.
To evaluate the efficacy of neurosteroids as a treatment for catamenial seizures.

Main Methods:

Utilized a rat pseudopregnancy model to simulate neurosteroid withdrawal and assess seizure susceptibility.
Examined the effects of neurosteroid withdrawal on anticonvulsant drug potency and GABA(A) receptor expression in an epilepsy model.

Main Results:

Neurosteroid withdrawal in rats increased susceptibility to chemoconvulsant seizures and spontaneous seizures.
Anticonvulsant drug efficacy (benzodiazepines, valproate) was reduced, while neurosteroids (allopregnanolone, ganaxolone) showed enhanced potency.
Changes in GABA(A) receptor subunit expression (e.g., alpha4) correlated with benzodiazepine resistance and altered neurosteroid sensitivity.

Conclusions:

Neurosteroid withdrawal significantly impacts seizure threshold and anticonvulsant drug effectiveness.
Neurosteroids and their analogs, like ganaxolone, show promise for treating catamenial epilepsy via neurosteroid replacement therapy.